METHOD FOR INTERMITTENT THERAPY IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA Russian patent published in 2014 - IPC G01N33/53 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to urology, and can be used for the intermittent therapy in patients suffering from benign prostatic hyperplasia (BPH). The patient is examined by clinical instrumental methods and prescribed with pharmaceuticals. The patient's total PSA and total testosterone in blood serum are measured before therapy involving Dutasteride 0.5 mg once a day and Tamsulosin 0.4 mg once a day and every 3 months after the therapy. A laboratory response rate marker $$\frac{\raisebox{1ex}{$PS{A}_1$}\!\left/ \!\raisebox{-1ex}{$T_1$}\right.}{\raisebox{1ex}{$PS{A}_2$}\!\left/ \!\raisebox{-1ex}{$T_2$}\right.}$$ is determined, wherein PSA₁ is the total pre-therapeutic PSA; PSA₂ is the total post-therapeutic PSA, T₁ is the total pre-therapeutic testosterone, T₂ is the total post-therapeutic testosterone. If the derived laboratory response rate marker is 3 or more, the prescribed therapy is considered to be withdrawn, and the derived laboratory response rate if being less than 3 requires the therapy to be proceeded with.

EFFECT: invention enables selecting the optimum length of treatment for each specific patient, reducing the length of therapy and drug load on the patient's body.

1 tbl, 2 ex